- Home
- WHF vs PLX Comparison
WHF vs PLX Comparison
Compare WHF & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | PLX |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.1M | 168.4M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | WHF | PLX |
|---|---|---|
| Price | $6.46 | $2.34 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.75 | ★ $12.00 |
| AVG Volume (30 Days) | 60.4K | ★ 677.8K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 13.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.35 | ★ $10.52 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.07 | $1.41 |
| 52 Week High | $9.06 | $3.19 |
Technical Indicators
Market Signals| Indicator | WHF | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 57.30 |
| Support Level | $6.40 | $2.06 |
| Resistance Level | $7.55 | $2.42 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 25.47 | 50.00 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.